BlueCross BlueShield of Tennessee Medical Policy Manual



50242-0070-XX GAZYVA 25 MG/ML Solution (GENENTECH)


Obinutuzumab is a monoclonal antibody which targets the CD20 antigen expressed on the surface of B-lymphocytes, both pre B-lymphocytes and mature B-lymphocytes.  When obinutuzumab binds with the CD20 antigen it causes B-cell lysis and cell death likely through three ways.  First, it causes engagement of immune effector cells; second, it directly activates intracellular death signaling pathways; third, activation of the complement cascade.  Once engaged, the immune effector cells mechanisms of cell death include antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis. 













Combination therapy:

§  100 mg day 1, 900 mg day 2, then 1000 mg days 8 and 15 of Cycle 1 (loading doses)

§  1000 mg on Day 1 of cycles 2-6 (cycles are 28 days)


§  100 mg day 1, 900 mg day 2, then 1000 mg days 8 and 15 of cycle 1 (loading doses)

§  1000 mg on Day 1 of cycles 2-8 (28-day cycle)


§  100 mg day 1, 900 mg day 2, 1000 mg day 3, 2000 mg day 8 and 15 of cycle 1 (loading doses)

2000 mg on Day 1 of cycles 2-8 (28-day cycle)







B-cell Lymphomas

Initial Combination therapy:

§  1000 mg days 1, 8, & 15 of cycle 1 (loading doses); given in combination with

chemotherapy or lenalidomide

  • Combination chemotherapy:

·         1000 mg day 1 of cycles 2-6 (28-day cycle) in combination with bendamustine

·         1000 mg day 1 of cycles 2-6 (21-day cycle) in combination with CHOP, followed by 2 additional 21-day cycles of Gazyva alone

·         1000 mg day 1 of cycles 2-8 (21-day cycle) with CVP


  • In combination with lenalidomide:

·         1000 mg day 1 of cycles 2-6 (28-day cycle)

Initial Monotherapy:

§  1000 mg once a week for 4 weeks on (days 1, 8, 15, & 22)

Maintenance therapy for use after initial combination therapy or monotherapy:

§  1000 mg every 2 months for up to two years as monotherapy

§  NOTE: When initial therapy is given in combination with lenalidomide, the first year of maintenance therapy will be given with lenalidomide, followed by an additional year of monotherapy


Refer to DOSAGE LIMITS below


BlueCross BlueShield of Tennessee’s Medical Policy complies with Tennessee Code Annotated Section 56-7-2352 regarding coverage of off-label indications of Food and Drug Administration (FDA) approved drugs when the off-label use is recognized in one of the statutorily recognized standard reference compendia or in the published peer-reviewed medical literature.


We develop Medical Policies to provide guidance to Members and Providers.  This Medical Policy relates only to the services or supplies described in it.  The existence of a Medical Policy is not an authorization, certification, explanation of benefits or a contract for the service (or supply) that is referenced in the Medical Policy.  For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed.  If there is a conflict between the Medical Policy and a health plan, the express terms of the health plan will govern.


For appropriate chemotherapy regimens, dosage information, contraindications, precautions, warnings, and monitoring information, please refer to one of the standard reference compendia (e.g., the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) published by the National Comprehensive Cancer Network®, Drugdex Evaluations of Micromedex Solutions at Truven Health, or The American Hospital Formulary Service Drug Information).


BlueCross BlueShield Association. Medical Policy Reference Manual. (10:2017). Uses of monoclonal antibodies for the treatment of non-Hodgkin lymphoma, including chronic lymphocytic leukemia, and acute myeloid leukemia in the non-hematopoietic stem-cell transplant setting (2.03.05). Retrieved June 18, 2018 from BlueWeb.

Lexicomp Online. (2020, March). AHFS DI. Obinutuzumab. Retrieved September 15, 2020 from Lexicomp Online with AHFS.

MICROMEDEX Healthcare Series. Drugdex Evaluations. (2020, June). Obinutuzumab. Retrieved September 15, 2020 from MICROMEDEX Healthcare Series.

National Comprehensive Cancer Network. (2020). NCCN Drugs & Biologics Compendium®. Obinutuzumab. Retrieved September 15, 2020 from the National Comprehensive Cancer Network.

U. S. Food and Drug Administration. (2020, March). Center for Drug Evaluation and Research. Gazyva® (obinutuzumab) for injection. Retrieved September 15, 2020 from




Policies included in the Medical Policy Manual are not intended to certify coverage availability. They are medical determinations about a particular technology, service, drug, etc. While a policy or technology may be medically necessary, it could be excluded in a member's benefit plan. Please check with the appropriate claims department to determine if the service in question is a covered service under a particular benefit plan. Use of the Medical Policy Manual is not intended to replace independent medical judgment for treatment of individuals. The content on this Web site is not intended to be a substitute for professional medical advice in any way. Always seek the advice of your physician or other qualified health care provider if you have questions regarding a medical condition or treatment.

This document has been classified as public information





Maximum billable units per dose and over time by indication as a Medical Benefit   1 billable unit = 10 mg



Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL):

Loading Dose:

10 billable units day 1, 90 billable units day 2, 100 billable units day 3, 200 billable units days 8 and 15 of Cycle 1  (21 days)

Maintenance Dose:

200 billable units every 21 days

All other indications:

Loading Dose:

100 billable units days 1, 8, 15 of Cycle 1 (28 days)

Maintenance Dose:

100 billable units every 21 days for 8 cycles; then every 2 months for 2 years